T
Troy A. Luster
Researcher at University of Texas Southwestern Medical Center
Publications - 10
Citations - 408
Troy A. Luster is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Bavituximab & Phosphatidylserine. The author has an hindex of 5, co-authored 9 publications receiving 396 citations. Previous affiliations of Troy A. Luster include University of Nebraska Medical Center.
Papers
More filters
Journal ArticleDOI
Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma.
TL;DR: Whether treatment with the murine equivalent of bavituximab, 2aG4, combined with irradiation can suppress tumor growth in a rat model of glioblastoma is determined.
Journal ArticleDOI
Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids
TL;DR: 2aG4 enhances the antitumor effects of radiation therapy by increasing antibody-dependent cell-mediated cytotoxicity toward tumor vessels with externalized phosphatidylserine.
Journal ArticleDOI
Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
Adam W. Beck,Troy A. Luster,Andrew F. Miller,Shane E. Holloway,Christopher R. Conner,Carlton C. Barnett,Philip E. Thorpe,Jason B. Fleming,Rolf A. Brekken +8 more
TL;DR: 3G4 enhanced the anti‐tumor and anti‐metastatic activity of gemcitabine without contributing to toxicity, and was less effective than the combination of the 2 agents together.
Journal ArticleDOI
Plasma Protein β-2-Glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells
Troy A. Luster,Jin He,Xianming Huang,Sourindra Maiti,Alan J. Schroit,Philip G. de Groot,Philip E. Thorpe +6 more
TL;DR: 3G4 targets tumor EC by increasing the avidity of β2 GP1 for anionic phospholipids through formation of multivalent 3G4-β2GP1 complexes, which indicates that antibody binding to PS is dependent on plasma protein β-2-glycoprotein 1.
Journal ArticleDOI
The Vascular-Ablative Agent VEGF121/rGel Inhibits Pulmonary Metastases of MDA-MB-231 Breast Tumors
Sophia Ran,Sophia Ran,Khalid A. Mohamedali,Troy A. Luster,Philip E. Thorpe,Michael G. Rosenblum +5 more
TL;DR: The antitumor vascular-ablative effect of VEGF(121)/rGel may be utilized not only for treating primary tumors but also for inhibiting metastatic spread and vascularization of metastases.